Aeolus Pharmaceuticals Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended June 30, 2015
For the nine months, the company reported contract revenue of $2,177,000 compared with $7,214,000 for the same period last year. Loss from operations was $2,194,000 compared with income from operations of $445,000 for the same period last year. Net loss was $2,194,000 or $0.02 diluted per share compared with net income of $445,000 or $0.00 diluted per share for the same period last year. Net cash used in operating activities was $1,121,000 compared with cash generated from operating activities of $403,000 for the same period last year.